Patent · US Active

Anti-GCC antibody molecules

US9156915B2 · kind B2 · utility

20Cited by

74References

17Claims

0Family size

Assignee

Thomas Jefferson University · US

Inventors

Scott A. Waldman · Ardmore, US
Michael S. Magee · Philadelphia, US
Adam E. Snook · Chester, US

Key dates

Filing date	Apr 26, 2013
Grant date	Oct 13, 2015
Priority date	—
Expiry date	Apr 26, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/988
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.